Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk.

Is GMAB or ALNY more profitable?

Genmab A/S has a net margin of 30.74% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Genmab A/S's return on equity of 18.90% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	30.74%	18.90%	16.83%
Alnylam Pharmaceuticals	-16.58%	N/A	-8.92%

Do institutionals and insiders hold more shares of GMAB or ALNY?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, GMAB or ALNY?

Genmab A/S has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Does the MarketBeat Community believe in GMAB or ALNY?

Alnylam Pharmaceuticals received 948 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 60.68% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 142 60.68%	Underperform Votes 92 39.32%
Alnylam Pharmaceuticals	Outperform Votes 1090 76.17%	Underperform Votes 341 23.83%

Which has stronger earnings & valuation, GMAB or ALNY?

Genmab A/S has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	7.97	$631.91M	$1.20	24.00
Alnylam Pharmaceuticals	$1.83B	10.66	-$440.24M	-$2.68	-57.47

Does the media prefer GMAB or ALNY?

In the previous week, Alnylam Pharmaceuticals had 17 more articles in the media than Genmab A/S. MarketBeat recorded 26 mentions for Alnylam Pharmaceuticals and 9 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.53 beat Alnylam Pharmaceuticals' score of 0.44 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	5 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate GMAB or ALNY?

Genmab A/S currently has a consensus target price of $48.50, indicating a potential upside of 67.53%. Alnylam Pharmaceuticals has a consensus target price of $216.19, indicating a potential upside of 40.05%. Given Genmab A/S's higher possible upside, equities analysts plainly believe Genmab A/S is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	3 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alnylam Pharmaceuticals	0 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.59

Summary

Genmab A/S beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks.